Aspira Women's Health Registers 29.2M Shares for Resale, No New Capital

TL;DR

**AWHL is registering a massive share dump by insiders, signaling potential dilution and a tough road ahead for new investors despite promising product pipeline.**

AI Summary

Aspira Women's Health Inc. (AWHL) filed an S-1/A on October 20, 2025, to register 29,226,527 shares of common stock for resale by selling stockholders. The company will not receive any proceeds from these sales. This offering includes 5,915,850 shares from the conversion of $1,370,000 in Senior Secured Convertible Promissory Notes issued on March 5, 2025. Additionally, 11,848,177 shares underlie Amended and Restated March 2025 Warrants, which saw their exercise price updated to $0.35 per share on September 19, 2025. The filing also covers 6,550,000 shares and warrants for 4,912,500 shares issued in a September 16, 2025 private placement at $0.45 per unit, with warrants exercisable at $0.75 per share. AWHL is focused on AI-powered noninvasive tests for gynecologic diseases, expanding its OvaWatch test in Q2 2024, which increased its addressable market tenfold from 200,000-400,000 to 2-4 million tests annually. The company is also developing OVAinform for ovarian cancer and ENDOinform for endometriosis, targeting addressable markets of 2,800,000 and over 6.5 million women, respectively.

Why It Matters

This S-1/A filing signals a significant potential dilution event for existing Aspira Women's Health (AWHL) shareholders, as nearly 30 million shares are being registered for resale without the company receiving any new capital. While the company is expanding its product pipeline with OvaWatch, OVAinform, and ENDOinform, targeting large addressable markets for gynecologic diagnostics, the overhang of these resale shares could pressure the stock price. Investors should weigh the company's growth prospects in a competitive diagnostic market against the potential for increased supply of shares. Employees and customers may see this as a necessary step for early investors to realize gains, but it doesn't directly fund new initiatives.

Risk Assessment

Risk Level: high — The filing explicitly states, 'Investing in our securities is highly speculative and involves a high degree of risk.' The registration of 29,226,527 shares for resale by selling stockholders, without the company receiving any proceeds, creates a significant overhang that could depress the stock price. Furthermore, the company is a 'smaller reporting company' with reduced disclosure requirements, which inherently carries higher risk for investors.

Analyst Insight

Investors should exercise extreme caution and thoroughly evaluate the potential for significant dilution from the 29,226,527 resale shares. Consider the impact of this supply on the OTCQB-listed stock, which closed at $0.52 on September 29, 2025, before making any investment decisions. Focus on the company's actual revenue and net income, which are not detailed in this specific filing, to assess fundamental value.

Key Numbers

• 29,226,527 — Shares of Common Stock (Total shares registered for resale by Selling Stockholders)
• $1,370,000 — Aggregate principal amount of Senior Secured Convertible Promissory Notes (Issued on March 5, 2025, and fully converted into Units)
• 5,915,850 — Shares of Common Stock (Issued from the conversion of Convertible Notes)
• 11,848,177 — Shares of Common Stock (Underlying the Amended and Restated March 2025 Warrants)
• $0.35 — Exercise price per share (Updated exercise price for Amended and Restated March 2025 Warrants)
• 6,550,000 — Shares of Common Stock (Issued pursuant to the September 2025 Purchase Agreement)
• 4,912,500 — Shares of Common Stock (Underlying the September 2025 Warrants)
• $0.45 — Purchase price per September 2025 Unit (Price for shares and warrants in September 2025 private placement)
• $0.75 — Exercise price per share (For September 2025 Warrants)
• $0.52 — Closing price per share (On OTCQB on September 29, 2025)

Key Players & Entities

• Aspira Women's Health Inc. (company) — Registrant
• Michael Buhle (person) — Chief Executive Officer and Chief Commercial Officer
• J. Eric Johnson (person) — Counsel for Registrant at Winston & Strawn LLP
• Securities and Exchange Commission (regulator) — Regulatory body for the filing
• Aspira Labs, Inc. (company) — Research and commercial CLIA laboratory owned by Aspira Women's Health Inc.
• March 2025 Purchasers (company) — Certain existing accredited investors
• September 2025 Purchasers (company) — Accredited and institutional investors
• OTCQB Market (company) — Stock exchange where AWHL is listed

FAQ

Risk Factors

• Trading on OTCQB [high — market]: The company's Common Stock is traded on the OTCQB, a less regulated market with lower financial standards than national exchanges. This can lead to increased volatility, potential for abuses, and difficulty for broker-dealers to recommend the stock due to FINRA suitability rules for speculative low-priced securities, potentially depressing the stock price.
• Dilution from Warrants and Options [medium — financial]: A significant number of shares (21,235,745) are issuable upon exercise of warrants with a weighted average exercise price of $0.98, and 1,852,045 shares from options with a weighted average exercise price of $1.19. This potential dilution could negatively impact the stock price and existing shareholders' equity.
• Future Share Issuance [medium — financial]: An additional 2,052,560 shares are reserved for future issuance under existing stock incentive plans. This further increases the potential for dilution, impacting the value of currently outstanding shares.

Industry Context

Aspira Women's Health operates in the diagnostic testing sector, specifically focusing on AI-powered noninvasive tests for gynecologic diseases. The industry is characterized by increasing demand for early detection and personalized medicine, with a growing emphasis on less invasive diagnostic methods. Competitors may include established diagnostic companies and emerging biotech firms developing novel testing platforms.

Regulatory Implications

As a healthcare technology company, Aspira is subject to stringent regulatory oversight from bodies like the FDA, particularly concerning the development, validation, and marketing of its diagnostic tests. Compliance with healthcare data privacy regulations (e.g., HIPAA) is also critical. The OTCQB listing implies a less regulated trading environment but still requires adherence to SEC reporting standards.

What Investors Should Do

1. Monitor Selling Stockholder Activity
2. Evaluate Dilution Potential
3. Assess Market Liquidity and Volatility
4. Track Commercialization Progress

Key Dates

• 2025-10-20: S-1/A Filing — Registers 29,226,527 shares for resale by selling stockholders, indicating potential for significant selling pressure without direct proceeds to the company.
• 2025-09-29: Closing Price on OTCQB — The stock closed at $0.52 per share, providing a current market valuation reference point for the shares being registered for resale.
• 2025-09-19: Warrant Exercise Price Update — Amended and Restated March 2025 Warrants had their exercise price updated to $0.35, potentially making them more attractive to exercise and leading to the resale of underlying shares.
• 2025-09-16: Private Placement — Issued units at $0.45 per unit, with warrants exercisable at $0.75. This indicates recent capital raising activity and the terms of those securities.
• 2025-03-05: Senior Secured Convertible Promissory Notes Issued — Notes totaling $1,370,000 were issued, which have since been converted into 5,915,850 shares, a key component of the current resale registration.
• 2024-02: OvaWatch Test Expansion — Expansion of the OvaWatch test in Q2 2024 significantly increased the addressable market, a key driver for the company's growth strategy.

Glossary

S-1/A

An amendment to a registration statement filed with the SEC. It's used to correct or supplement information previously filed on an S-1 form, often for the resale of securities by existing stockholders. (This filing is an S-1/A, indicating it's primarily for the resale of shares by selling stockholders, not for raising new capital for the company.)

Selling Stockholders

Existing holders of a company's securities who are registering their shares for resale to the public. The company does not receive proceeds from these sales. (The primary purpose of this S-1/A is to allow these stockholders to sell their shares, which could impact market supply and price.)

Convertible Promissory Notes

Debt instruments that can be converted into a predetermined amount of equity (stock) in the issuing company. ($1,370,000 in these notes were converted into 5,915,850 shares, contributing to the shares being registered for resale.)

Warrants

Securities that give the holder the right, but not the obligation, to purchase a company's stock at a specified price (exercise price) before a certain expiration date. (Significant numbers of shares are registered for resale underlying these warrants, with updated exercise prices affecting their potential conversion.)

Private Placement

A sale of securities directly to a select group of investors, rather than through a public offering. (The company recently conducted a private placement, issuing shares and warrants, which are part of the securities covered by this S-1/A.)

Addressable Market

The total potential market demand for a company's product or service. (The company highlights significant expansion in the addressable market for its diagnostic tests, indicating growth potential.)

OTCQB

An over-the-counter quotation service for early-stage and developing companies. It has less stringent listing requirements than major stock exchanges. (The company's stock trades on the OTCQB, which is associated with higher volatility and regulatory considerations.)

Year-Over-Year Comparison

This S-1/A filing focuses on the resale of existing shares by stockholders, rather than a primary offering to raise capital. Key metrics like revenue, net income, and margins are not detailed in this specific filing, making a direct comparison of financial performance difficult. However, the filing highlights recent financing activities, including the conversion of debt and a private placement, and updates on warrant terms, indicating ongoing corporate actions and potential shifts in the capital structure.

Key Financial Figures

• $0.001 — ”) of common stock, par value of $0.001 per share (the “ Common Stock &rd
• $1,370,000 — d sold an aggregate principal amount of $1,370,000 of Senior Secured Convertible Promissor
• $0.25 — which are exercisable for five years at $0.25 per share for the first 24 months after
• $0.50 — the first 24 months after issuance and $0.50 per share thereafter (the “ March
• $0.35 — pplicable to the March 2025 Warrants to $0.35 per share and removed the ability to ca
• $0.45 — of Common Stock at a purchase price of $0.45 per September 2025 Unit. The September
• $0.75 — e upon issuance at an exercise price of $0.75 per share and have a term of exercise e
• $0.52 — re of our Common Stock on the OTCQB was $0.52. We are a “smaller reporting co
• $700 million — res held by non-affiliates is less than $700 million and our annual revenue was less than $1
• $100 million — on and our annual revenue was less than $100 million during the most recently completed fisc
• $7,831,237 — e holders of the Warrants, estimated at $7,831,237. See “ Use of Proceeds ” fo
• $0.98 — th a weighted average exercise price of $0.98 per share; 1,852,045 shares of Common
• $1.19 — th a weighted average exercise price of $1.19 per share; and 2,052,560 shares of Co

Filing Documents

• forms-1a.htm (S-1/A) — 290KB
• ex5-1.htm (EX-5.1) — 13KB
• ex23-1.htm (EX-23.1) — 4KB
• ex107.htm (EX-FILING FEES) — 28KB
• forms-1a_001.jpg (GRAPHIC) — 7KB
• ex5-1_001.jpg (GRAPHIC) — 6KB
• 0001493152-25-018669.txt ( ) — 475KB
• ex107_htm.xml (XML) — 6KB

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 14 SELLING STOCKHOLDERS 17 PLAN OF DISTRIBUTION 18 LEGAL MATTERS 22 EXPERTS 22 WHERE YOU CAN FIND MORE INFORMATION 22 INCORPORATION OF DOCUMENTS BY REFERENCE 23 i ABOUT THIS PROSPECTUS You should carefully read this prospectus before deciding to invest in our securities. We have not authorized anyone to provide you with additional information or information different from that contained or incorporated by reference in this prospectus filed with the Securities and Exchange Commission (the “ SEC ”). We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The Selling Stockholders are offering to sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted. The information contained in this prospectus, or any document incorporated by reference in this prospectus, is accurate only as of the date of those respective documents, regardless of the time of delivery of this prospectus or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. The information provided or incorporated by reference in this prospectus contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. We obtained the industry and market data in this prospectus or in the documents incorporated by reference into this prospectus from our own research as well as from industry and general publications, surveys and studies conducted by third parties. This data involves a number of assumptions and limitations and contains projections and estimates of the future performance of the industry in which we operate that are subject to a high degree of uncertainty, including those discussed in “ Risk Factors .” We caution you not to give undue weight to su

Use of Proceeds

Use of Proceeds We will not receive any proceeds from the sale of the Resale Shares by the Selling Stockholders. Upon the exercise of the Amended and Restated 2025 Warrants or the September 2025 Warrants by payment of cash, we will receive the nominal cash exercise price paid by the holders of the Warrants, estimated at $7,831,237. See “ Use of Proceeds ” for a more complete description.

Risk Factors

Risk Factors Investing in our securities is highly speculative and involves a high degree of risk. See “ Risk Factors ” beginning on page 7 of this prospectus, and the other information included or incorporated by reference in this prospectus for a discussion of factors you should consider carefully before deciding to invest in our securities. OTC Symbol for our Common Stock “AWHL” (1) The number of shares of our Common Stock to be outstanding after this offering is based on 42,655,918 shares of Common Stock outstanding as of September 29, 2025, and excludes: 21,235,745 shares of Common Stock issuable upon exercise of warrants with a weighted average exercise price of $0.98 per share; 1,852,045 shares of Common Stock issuable upon exercise of options with a weighted average exercise price of $1.19 per share; and 2,052,560 shares of Common Stock reserved for future issuance under our existing stock incentive plan. 6

RISK FACTORS

RISK FACTORS Investing in our Common Stock involves a high degree of risk. Before making an investment decision, you should carefully consider the risks described in the sections entitled “ Risk Factors ” in our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as filed with the SEC, which are incorporated herein by reference in their entirety, as well as any amendment or updates to our risk factors reflected in subsequent filings with the SEC, including any amendment or supplement to this prospectus or any report incorporated herein by reference. Our business, financial condition, results of operations or prospects could be materially adversely affected by any of these risks. The trading price of our securities could decline due to any of these risks, and you may lose all or part of your investment. This prospectus and the documents incorporated herein by reference also contain forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks mentioned elsewhere in this prospectus. For more information, see the below section “ Where You Can Find Additional Information .” Please also read carefully the above section “ Information Regarding Forward-Looking Statements .” Risks Related to our Common Stock Our Common Stock is currently traded on the OTCQB, which may have an unfavorable impact on our stock price and liquidity. Our Common Stock is currently quoted on the OTCQB. The OTCQB is significantly more limited market than the national securities exchanges such as the New York Stock Exchange, or Nasdaq stock exchange, and there are lower financial or qualitative standards that a company must meet to have its stock quoted on the OTCQB. OTCQB is an inter-dealer quotation system much less regulated than the major exchanges, and trading in our Common St

View Full Filing

View this S-1/A filing on SEC EDGAR